Header Image

Latest News

Latest News

Filter Releases
 
Latest News
Date Title and Summary View
Sep 15, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the completion of an underwritten public offering of 17,864,078 shares of its common stock, including 2,330,097 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.  The g...
Sep 12, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the pricing of an underwritten public offering of 15,533,981 shares of its common stock, offered at a price to the public of $5.15 per share.  The gross proceeds from this offering to BioCryst are expected to be $80 millio...
Sep 11, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering to sell $80 million of its common stock in an underwritten public offering. As pa...
Sep 5, 2017
73% Reduction in Overall Attack Frequency at 125mg Dose (p...
Sep 4, 2017
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company will host a conference call on Tuesday, September 5, 2017, at 9:00 a.m. Eastern Time to provide an update on the Company's activities and progress. To participate in the conference call, pl...
Aug 23, 2017
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences: The Robert W. Baird's 2017 Global Healthcare Con...
Aug 7, 2017
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2017. "We are excited by the positive results previously reported in Parts 1 and 2 of the APeX-1 clinical trial that indicate we have an active oral drug, and loo...
Aug 2, 2017
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first subject into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353 given as a single oral dose for the acute treatment of angioedema attacks in patients ...
Jul 24, 2017
RESEARCH TRIANGLE PARK, N.C., July 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2017 financial results will be reported on Monday, August 7, 2017. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an upda...
Jun 13, 2017
RESEARCH TRIANGLE PARK, N.C., June 13, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the JMP Securities 2017 Life Sciences Conference in New York on Wednesday, June 21, 2017 ...
Jun 5, 2017
RESEARCH TRIANGLE PARK, N.C., June 05, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for a pediatric indication of RAPIVAB® (peramivir injection), which  was submitted in March 2017. Th...
May 31, 2017
RESEARCH TRIANGLE PARK, N.C., May 31, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Jefferies 2017 Global Healthcare Conference in New York on Tuesday, June 6, 2017 at 10...
May 30, 2017
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the appointment of Robert A. Ingram as Chairman of its Board of Directors. Following the Company's annual meeting on May 24, 2017, Robert A. Ingram will serve as Chairman of the Board of Directors and George B. Abercrombie w...
May 25, 2017
RESEARCH TRIANGLE PARK, N.C., May 25, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and ...
May 9, 2017
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 16, ...
Page:
...
Next Last